No. | Topic | Coverage |
1 | Diseases to be addressed | WG, MPA, CSS, PAN, cryoglobulinemic vasculitis, GCA, Takayasu arteritis |
2 | Initial assessment | Involvement of expert centres, structured clinical examination, role of ANCA, staging of disease, biopsy |
3 | Remission induction | Cyclophosphamide, methotrexate, high-dose glucocorticoids, doses, route of administration, regimen of intravenous use, prophylaxis against Pneumocystis jiroveci and osteoporosis, tapering of glucocorticoids, bladder protection, antiemetic therapy, monitoring for drug toxicity, plasmapheresis |
4 | Remission maintenance | Choice of immunomodulator, length of treatment, co-trimoxazole |
5 | Relapsing disease | Choice of immunomodulator, referral to expert centre |
6 | Refractory disease | Choice of immunomodulator, experimental therapies |
7 | Cryoglobulinemic vasculitis | Choice of therapy, antiviral therapy |
8 | Polyarteritis nodosa | Choice of therapy, antiviral therapy |
9 | Monitoring and follow-up | Structured clinical examination, blood test monitoring, urine analysis, vaccination, fertility and contraception |
10 | Complications of disease | Anaemia, hypertension, thromboprophylaxis, reconstructive surgery, renal protection |
ANCA, anti-neutrophilic cytoplasmic antibodies; CSS, Churg–Strauss syndrome; GCA, giant cell arteritis; MPA, microscopic polyangiitis; PAN, polyarteritis nodosa; WG, Wegener granulomatosis.